Fosamprenavir Expanded Access

You may be eligible if

• HIV-1 infected subjects.
• Subjects must belong to one of the following populations:
• 1. Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs.
• 2. Subjects who already receive amprenavir (Agenerase®)
• 3. Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.